InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,564.11
(
1.00%
)
US TECH 100
19,839.60
(
1.01%
)
Dow Jones
39,357.85
(
0.13%
)
Brent Oil
86.45
(
-1.01%
)
Bitcoin
56,375.01
(
-1.06%
)
Post# of 252491
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119981
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Fred Kadiddlehopper post# 251651

Thursday, 05/02/2024 1:11:42 PM

Thursday, May 02, 2024 1:11:42 PM

Post# of 252491
NVO 1Q24 sales for T2D/obesity drugs:

https://ml-eu.globenewswire.com/Resource/Download/01af84ed-a119-435a-9553-ddd08340ba2d

• Ozempic $3.9B, +43% YoY in constant currency

• Wegovy $1.3B, +107% YoY in constant currency

• Rybelsus $0.7B, +17% YoY in constant currency

Note: Ozempic and Wegovy are the same drug (at different recommended doses) for T2D and obesity, respectively. Rybelsus is an oral formulation of the same drug approved for T2D.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up